Heterogeneity of anti-phospholipid and anti-endothelial cell antibodies

12Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The role of the anti-phospholipid antibodies (APLA) and anti- endothelial cell antibodies (AECA) in the pathogenesis of anti-phospholipid syndrome (APS) is unclear. Differences in the reported involvement of APLA may be due, in part, to the polyclonal nature of these antibodies and the use of serum and serum fractions for analysis. To circumvent this issue, we generated monoclonal antibodies (MAB) from three patients with APS and two healthy controls. We then compared the antigen binding patterns and the heavy chain variable region (V(H)) DNA sequences of the MAB derived from patients with APS to those from healthy controls. The results of this study indicate that APLA and AECA comprise a highly heterogeneous population of antibodies with respect to the antigens they recognize, as well as V(H) gene usage. MAB derived from patients with APS do not differ from those derived from normal individuals based on either antigen recognition or V(H) gene usage. These results suggest the importance of additional predisposing factors in the pathogenesis of APS.

Cite

CITATION STYLE

APA

Shan, H., Goldman, J., Cunto, G., Manuppello, J., Chaiken, I., Cines, D. B., & Silberstein, L. E. (1998). Heterogeneity of anti-phospholipid and anti-endothelial cell antibodies. Journal of Autoimmunity, 11(6), 651–660. https://doi.org/10.1006/jaut.1998.0242

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free